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ABSTRACT
Objective In patients with non- ischaemic cardiomyopathy 
and reduced left ventricular ejection fraction (LVEF), 
normalisation of LVEF is associated with improved 
outcomes. However, data on patients with ischaemic 
cardiomyopathy and recovered LVEF are lacking. The goal 
of this study was to assess the prognostic significance 
of normalisation of the LVEF in patients with ischaemic 
cardiomyopathy.
Methods/Results We performed a non- prespecified post 
hoc analysis of the Surgical Treatment for Ischaemic Heart 
Failure (STICH) trial to determine the association between 
normalisation of LVEF (>50%) and mortality during follow- 
up. Of the 1212 patients with LVEF <35% enroled in 
the STICH trial, 932 underwent assessment of LVEF at 4 
months and/or 2 years after enrolment. Among them, 18 
patients experienced normalisation in LVEF at 4- month 
follow- up and 35 patients experienced recovery in LVEF 
at 2 years. Recovery of LVEF at 4 months and recovery 
of LVEF at 2 years were not correlated. Recovery of LVEF 
at 4 months was not associated with reduced all- cause 
mortality in unadjusted analysis (log- rank test p=0.54) or 
in Cox proportional hazards analysis (HR: 0.93; 95% CI: 
0.48 to 1.80; p=0.82). Ejection fraction recovery at 2 years 
was associated with a reduction in all- cause mortality, 
both in unadjusted analysis (log- rank test p=0.004) and in 
the Cox proportional hazard model (HR: 0.41; 95% CI: 0.21 
to 0.80; p=0.009).
Conclusions In patients with ischaemic cardiomyopathy, 
delayed normalisation of LVEF is associated with reduced 
mortality, whereas early recovery of LVEF is not. Further 
studies are needed to confirm these findings.
INTRODUCTION
As management strategies for heart failure 
with reduced ejection fraction (HFrEF) 
continue to improve, more patients experi-
ence improvement in left ventricular ejection 
fraction (LVEF) to a normal range (>50%). 
Several studies have suggested that even 
though recovery of LVEF typically does not 
correspond to a true normalisation of myocar-
dial function,1 2 it is associated with a marked 
improvement in outcomes.2 3 However, 
these analyses have focused on cohorts with 
a majority, or exclusively, of patients with 
heart failure of non- ischaemic aetiology.3–7 
In the landmark study that introduced the 
concept of heart failure with recovered LVEF, 
Basuray et al studied a cohort in which only 
16% of patients had ischaemic cardiomyo-
pathy (ICM).3 Other studies that focused on 
outcomes in patients with normalised LVEF 
included a percentage of patients with ICM 
ranging from 0%6 7 to 35%.5
Epidemiological data suggest that the 
timing and biology of reverse cardiac 
remodelling and ‘apparent healing’ differs 
depending on the aetiology of heart failure.8 
Key questions
What is already known about this subject?
 ► Many patients with non- ischaemic cardiomyopathy 
experience reverse left ventricular remodelling to 
the point of regaining an ejection fraction in the nor-
mal range. This is associated with an improvement 
in prognosis. In patients with ischaemic cardiomy-
opathy normalisation of left ventricular ejection frac-
tion (LVEF) is much less common and its prognostic 
significance is unclear.
What does this study add?
 ► Through a non- prespecified post- hoc analysis 
of patients enroled in the Surgical Treatment for 
Ischaemic Heart Failure trial, we found that patients 
with ischaemic cardiomyopathy can experience ear-
ly or delayed normalisation in LVEF. The two events 
are rare and are not correlated. Delayed normalisa-
tion in LVEF is associated with reduced mortality, 
early normalisation is not.
How might this impact on clinical practice?
 ► This study indicates that clinicians caring for pa-
tients with ischaemic cardiomyopathy and reduced 
LVEF can interpret delayed normalisation in LVEF as 
a positive prognostic marker but should interpret 
early normalisation in LVEF with caution.
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In particular, patients with ICM are less likely to experi-
ence normalisation in LVEF,5 9 and they are likely to have 
focal areas of permanent myocardial damage that are 
independent predictors of poor outcome.10 Therefore, it 
is unclear whether findings based on cohorts of patients 
highly enriched in heart failure of non- ischaemic aeti-
ology apply to patients with ICM and recovered LVEF. It 
also remains unclear what prognostic value a normalised 
LVEF holds in this patient population.
In order to start filling this gap in knowledge, we anal-
ysed data collected in the Surgical Treatment for Isch-
aemic Heart Failure (STICH) trial. The STICH trial was 
designed to compare the benefit of surgical revascular-
isation with medical therapy to that of medical therapy 
alone in patients with ICM and LVEF <35%.8 Patients 
were assessed with follow- up echocardiogram at 4 months 
and 2 years postrandomisation and were followed for 10 
years to assess mortality.11 12
METHODS
Data source
The STICH dataset was obtained from the NHLBI under 
a data use agreement. The Washington University Human 
Research Protection Office granted this study an exemp-
tion from Institutional Review Board oversight due to the 
de- identified nature of the data.
Study population
The rationale and methodology for patient selection 
in the STICH trial have been described previously.13 In 
brief, STICH was an international, multicentre, non- 
blinded, randomised trial. Patients included in the study 
had coronary artery disease, were eligible for coronary 
artery bypass graft (CABG) surgery and had a LVEF ≤35%. 
Patients were then randomised to one of three treatment 
arms: optimal medical therapy (OMT), CABG plus OMT 
or CABG plus OMT and surgical ventricular repair. For 
this study, we analysed only patients randomised to the 
CABG plus OMT or OMT alone (hypothesis 1).
Of the 1212 patients with LVEF ≤35% enroled in the 
STICH trial and randomised to OMT or CABG plus OMT, 
932 underwent echocardiographic assessment of LVEF at 
4 months and/or 2 years, while 587 patients had LVEF 
assessment at both time points. No assessment was done 
at other times. A total of 267 subjects without recorded 
ejection fraction (EF) were excluded. Two subjects with 
baseline EF >50% were also excluded. There were also 11 
patients with EF reported after date of death who were 
excluded. We defined LVEF recovery as LVEF >50%. In 
the STICH trial, LVEF was measured either via visual esti-
mate or biplane method, and measurements obtained 
with these two methods within this cohort were highly 
correlated.14
Statistical analysis
Baseline clinical data are represented as median with IQR 
for continuous variables and as counts with percentages 
for categorical data. The McNemar test was used to assess 
the relationship between LVEF recovery at 4 months 
and LVEF recovery at 2 years. Mortality was compared 
between patients with recovered LVEF and patients 
without recovered LVEF at 4 months or 2 years with 
multivariate Cox proportional hazard models. Because 
patients in the STICH trial did not have information 
on recovery status between 4 months and 2 years, and 
because most patients who recovered at 4 months did 
not retain their recovery status (described in the Results 
section), a time to recovery variable could not be accu-
rately calculated. We therefore decided against including 
the recovery status as a time- dependent variable in the 
Cox proportional hazard model. Likewise, we could not 
include 4- month and 2- year recovery as two independent 
predictors in one model, as a subject would have to be 
alive at 2 years in order to have an assessment at that time 
and not all patients alive at 4 months were alive at 2 years. 
Instead, we assessed early and late recovery separately. 
For the 4- month recovery model, the time to event was 
calculated from 4- month status assessment; for the 2- year 
model, it was calculated starting from 2- year assessment. 
The proportional hazard assumptions were tested, and 
appropriate diagnostics were performed. Three patients 
were censored over the course of long- term follow- up 
because of missing information. We included variables 
known to correlate with mortality in patients with ICM 
as covariates: age, body mass index (BMI), diabetes, sex, 
randomisation to CABG versus medical therapy and 
OMT. OMT was defined as therapy with aspirin, statin, 
beta blocker and ACE inhibitor or angiotensin receptor 
blocker at 4 months postrandomisation. Because of low 
frequencies, implanted cardiac defibrillator (ICD) and 
cardiac resynchronisation therapy (CRT) implantation 
variables were excluded from the models. The existing 
literature indicates that in the STICH trial CABG was not 
independently associated with LVEF improvement but 
was associated with mortality.15 To test whether the effect 
of LVEF improvement on survival was different for CABG 
versus medical therapy, we investigated the interaction 
between therapy type and LVEF recovery. The interac-
tion was insignificant for the 4- month time point and the 
2- year time point (p values 0.379 and 0.753, respectively), 
and therefore was not included in the final models.
RESULTS
Patient characteristics
Of the 1212 patients with LVEF ≤35% enroled in the 
STICH trial, 932 underwent assessment of LVEF at 4 
months and/or 2 years after enrolment. The 932 patients 
included in our analysis did not differ significantly from 
the STICH population not included in the analysis with 
respect to demographics and randomised treatment 
assignment to OMT plus CABG or OMT alone, they 
had slightly higher prevalence of diabetes (41% vs 33%, 
p=0.02) and slightly lower prevalence of CRT (7% vs 11%, 
p=0.04, table 1). Among them, 18 patients experienced 
normalisation in LVEF (>50%) at 4- month follow- up 
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and 35 patients experienced recovery in LVEF (>50%) 
at 2 years.
Relationship between LVEF recovery at 4 months and LVEF 
recovery at 2 years
A total of 587 patients had LVEF information at both 4 
months and 2 years. There was a weak correlation between 
LVEF at 4 months and LVEF at 2 years (Spearman corre-
lation 0.56, p<0.0001). However, there was no consistency 
in LVEF recovery status between 4 months and 2 years 
(McNemar test p=0.0005, figure 1). Of 11 patients who 
had recovered LVEF at 4 months and had a 2- year LVEF 
measurement, only three continued to have LVEF >50% 
at 2 years (right upper quadrant in figure 1).
Relationship between LVEF recovery at 4 months and mortality
A total of 885 patients had LVEF measurements at 4 
months. These 885 patients did not differ significantly 
from the patients who did not have LVEF measurement 
at 4 months with respect to demographics, comorbidities 
and randomisation to OMT plus CABG or OMT alone 
(online supplemental table 1). Of these 885 patients, 
18 were found to have recovered LVEF, while 867 were 
found to have reduced LVEF. Patients with recovered 
LVEF at 4 months were similar to patients with reduced 
LVEF in terms of age, gender, BMI, prevalence of ICDs or 
CRT and randomisation group within the STICH trial but 
had a trend towards higher prevalence of diabetes that 
was statistically insignificant (66.7% vs 41.1%, p=0.052, 
table 2). LVEF recovery at 4 months was not associated 
with reduced all- cause mortality during follow- up in 
unadjusted analysis (Kaplan- Meyer log- rank p=0.54, 
figure 2) or in the Cox proportional hazards model (HR: 
0.93; 95% CI: 0.48 to 1.80; p=0.82; table 3).
Table 1 Comparison between patients with LVEF assessment (included in this study) and patients without LVEF assessment 
(excluded from this study)
Comorbidity STICH Included Excluded P value included vs excluded
Age, mean (SD) 60 (9) 61 (9) 59 (9) 0.11
BMI (SD) 27 (5) 27 (5) 27 (5) 0.06
Medical therapy vs CABG, N (%) 590 (50) 476 (51) 114 (45) 0.09
Male, N (%) 1042 (88) 810 (87) 232 (91) 0.07
Diabetes, N (%) 468 (39) 385 (41) 83 (33) 0.02
CRT (%) 92 (8%) 64 (7%) 28 (11%) 0.04
ICD (%) 28 (2%) 24 (3%) 4 (2%) 0.49
Data are presented as mean (SD) for continuous variables and number (percentage) for categorical variables. Patients included and excluded 
from the analysis were compared using t- test for continuous variables and χ2 test for categorical variables.
STICH refers to all patients included in the STICH trial. Included refers to subgroup of STICH trial patients who had LVEF assessment during 
follow- up and were included in this study. Excluded refers to subgroup of STICH trial patients who did not have LVEF assessment during 
follow- up and were excluded from this study. Medical therapy versus CABG refers to patients randomised to medical therapy alone or to 
coronary artery bypass graft plus medical therapy.
BMI, body mass index; CABG, coronary artery bypass graft; CRT, cardiac resynchronisation therapy; ICD, permanent implanted cardiac 
defibrillator; LVEF, left ventricular ejection fraction; STICH, Surgical Treatment for Ischaemic Heart Failure.
Figure 1 Relationship between LVEF at 4 months and LVEF 
at 2 years: each patient with LVEF measurements at both 
4 months and 2 years is represented on the plot as a dot. 
Red lines mark LVEF=50% and identify four quadrants. The 
lower left quadrant includes patients with LVEF <50% at 
both 4 months and 2 years, the upper left quadrant includes 
patients with LVEF >50% at 2 years but <50% at 4 months, 
the upper right quadrant includes patients with LVEF 
>50% at both time points and the lower right quadrant 
includes patients with LVEF >50% at 4 months and LVEF 
<50% at 2 years. The dots are grouped along the diagonal, 
suggesting correlation between LVEF at 4 months and LVEF 
at 2 years. However, the number of dots in the right upper 
quadrant is much lower than the number of dots in the upper 
left quadrant + lower right quadrant indicating significant 
disagreement between LVEF recovery at 4 months and LVEF 
recovery at 2 years (McNemar test p=0.00047). LVEF, left 
ventricular ejection fraction.
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Relationship between LVEF recovery at 2 years and mortality
A total of 1116 patients survived for at least 2 years. Of these, 
634 patients had LVEF measurements at 2 years and were 
therefore included in the analysis of survival post 2- year 
landmark. These patients were less likely to be male (85.5% 
vs 91.5%, p=0.04) but did not differ from the rest of the 
cohort with respect to other demographics, comorbidi-
ties and randomisation to OMT plus CABG or OMT alone 
(online supplemental table 2). Of these 634 patients, 35 
were found to have recovered LVEF, while 599 were found to 
have reduced LVEF. Patients with recovered LVEF at 2 years 
were similar to patients with reduced LVEF in terms of age, 
BMI, prevalence of ICDs, prevalence of CRT, prevalence of 
diabetes and randomisation group within the STICH trial but 
were less likely to be male (71.4% vs 86.3%, p=0.03, table 4). 
Table 2 Comparison between patients with and without 
LVEF recovery at 4 months
LVEF ≤50% 
at 4 months 
(n=867)
LVEF >50% 
at 4 months 
(n=18) P value
Age (SD) 60.57 (9.29) 60.81 (8.02) 0.915
BMI (SD) 27.43 (4.71) 27.93 (3.91) 0.654
Medical therapy vs 
CABG (%)
449 (51.8) 6 (33.3) 0.189
Male gender (%) 755 (87.1) 13 (72.2) 0.136
Diabetes (%) 356 (41.1) 12 (66.7) 0.052
CRT=Yes (%) 57 (6.6) 3 (16.7) 0.117
OMT 567 (65.4) 12 (66.7) 1
ICD 22 (2.5) 0 (0.0) 1
Data presented as mean (SD) for continuous variables and number 
(percentage) for categorical variables. Patients with and without 
recovered LVEF at 4 months were compared using t- test for 
continuous variables and χ2 test for categorical variables.
Medical therapy versus CABG refers to patients randomised to 
medical therapy alone or to CABG plus medical therapy. OMT 
refers to patient on OMT at 4 months follow- up.
BMI, body mass index; CABG, coronary artery bypass graft; CRT, 
cardiac resynchronisation therapy; ICD, permanent implanted 
cardiac defibrillator; LVEF, left ventricular ejection fraction; OMT, 
optimal medical therapy.
Figure 2 Association between LVEF recovery at 4 months 
and mortality survival probability for patients LVEF >50% at 4 
months is depicted in red, survival probability of patients with 
LVEF <50% at 4 months is depicted in black. For each year 
mark on the X- axis the number of subjects at risk in the two 
groups is reported above the axis, LVEF <50% on top, LVEF 
>50% on the bottom. Kaplan- Meier log- rank test p=0.54. 
LVEF, left ventricular ejection fraction.
Table 3 Relationship between LVEF recovery at 4 months 
and mortality
HR (CI) P value
LVEF recovery at 4 months 0.93 (0.48 to 1.80) 0.82
Age, per decade 1.37 (1.24 to 1.51) <0.0001
Medical therapy vs CABG 1.45 (1.21 to 1.73) <0.0001
OMT 0.82 (0.68 to 0.98) 0.031
Diabetes 1.29 (1.08 to 1.54) 0.006
Female gender 0.61 (0.46 to 0.82) 0.001
BMI 1.00 (0.98 to 1.02) 0.828
Cox proportional hazard model of the relationship between LVEF 
recovery at 4 months and mortality during follow- up. For each 
variable, the HR for mortality during follow- up after adjusting for all 
other listed variables is indicated. 95% CI for the HR is reported 
in parentheses. Medical therapy vs CABG refers to patients 
randomised to medical therapy alone or to CABG plus medical 
therapy. OMT refers to patient on OMT at 4 months follow- up.
BMI, body mass index; CABG, coronary artery bypass graft; LVEF, 
left ventricular ejection fraction; OMT, optimal medical therapy.
Table 4 Comparison between patients with and without 
LVEF recovery at 2 years
LVEF ≤50% 
at 2 years 
(n=599)
LVEF >50% 
at 2 years 
(n=35) P value
Age (SD) 60.22 (9.28) 61.02 (6.65) 0.616
BMI (SD) 27.48 (4.54) 27.46 (6.01) 0.977
Medical therapy vs 
CABG (%)
308 (51.4) 13 (37.1) 0.142
Male gender (%) 517 (86.3) 25 (71.4) 0.029
Diabetes (%) 242 (40.4) 20 (57.1) 0.075
CRT (%) 39 (6.5) 1 (2.9) 0.717
OMT (%) 404 (67.4) 26 (74.3) 0.512
ICD (%) 13 (2.2) 0 (0.0) 1
Data presented as mean (SD) for continuous variables and 
number (percentage) for categorical variables. Patients with and 
without recovered LVEF at 2 years were compared using t- test for 
continuous variables and χ2 test for categorical variables. OMT 
refers to patient on OMT at 4 months follow- up.
BMI, body mass index; CABG, coronary artery bypass graft; CRT, 
cardiac resynchronisation therapy; ICD, permanent implanted 
cardiac defibrillator; LVEF, left ventricular ejection fraction; OMT, 
optimal medical therapy.
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Recovery of LVEF at 2 years was associated with a reduction 
in all- cause mortality during follow- up, both in unadjusted 
survival analysis (log- rank p=0.004, figure 3) and in the in 
the multivariate Cox proportional hazards model (HR: 0.41; 
95% CI: 0.21 to 0.80; p=0.009; table 5).
DISCUSSION
We performed a non- prespecified analysis of the STICH 
trial, the only contemporary randomised treatment trial 
of patients with ischaemic heart failure. We found that 
in patients with ICM: (1) recovery of LVEF at short- term 
follow- up (4 months) does not correlate with recovery of 
LVEF at long- term follow- up(figure 1); (2) normalisation 
of LVEF in the short- term might not be a meaningful 
prognostic marker(figure 2, table 3); (3) Normalisation 
of LVEF at long- term (2 years) follow- up correlates with 
a reduced hazard of death (figure 3, table 4). These find-
ings expand our current understanding of LVEF normal-
isation in patients with ICM and are relevant to clinical 
practice.
Many patients with HFrEF of non- ischaemic aetiology 
experience a significant improvement in LVEF in the first 
year as a response to OMT. This improvement is typically 
an intermediate state before a subsequent deteriora-
tion and very seldom (if at all) marks the beginning of 
a permanent normalisation of LVEF.15 Patients with ICM 
tend to experience less improvement in LVEF than those 
with non- ischaemic disease, and seldom recover LVEF in 
the normal range.5 9 16 Data on LVEF trajectory in patients 
with normalised LVEF and ICM is nearly absent. In this 
study, we confirmed that normalisation of LVEF is a rare 
occurrence in patients with ICM. In addition, we found 
that while LVEF at short- term follow- up (4 months) 
following initiation of therapy correlated with LVEF at 
long- term follow- up (2 years), there was no correlation 
between early and late normalisation in LVEF. This is a 
novel and unexpected finding. LVEF is typically used as 
a surrogate of myocardial function, but is a measure that 
incorporates multiple cardiovascular factors, including 
preload, afterload (effective arterial elastance), inotropy 
(LV end- systolic elastance) and left ventricular stiffness.17 
Accordingly, changes in different cardiovascular and 
haemodynamic parameters can result in an improvement 
in LVEF without an improvement in intrinsic myocardial 
contractile function. This is exemplified by the observa-
tion that treatment with negative inotropic agents such 
as beta- blockers can improve EF as early as 2 weeks after 
initiation of therapy.18 We therefore hypothesise that, 
in response to medical therapy, some patients with ICM 
may experience changes in several cardiovascular factors 
that affect LVEF, and that this might result in rapid, but 
ephemeral, improvement of LVEF to a normal range.
We found that normalisation in LVEF at 4 months was 
not associated with decreased mortality during follow- up, 
while normalisation in LVEF at 2 years was associated with 
mortality improvement. The observation of a correlation 
between recovered LVEF at 2 years and reduced mortality 
is novel because the literature reports no data on the 
prognostic significance of LVEF normalisation in patients 
with ICM, though it does parallel findings in cohorts of 
patients with non- ischaemic disease.3–7 19–21 The observa-
tion that rapid recovery in LVEF does not correlate with 
improved survival is both novel and unexpected insofar 
as normalisation in LVEF has been, to date, uniformly 
considered a positive prognostic factor.3 5 Patients with 
normalised LVEF at 4 months had a modest increase 
in the prevalence of diabetes of borderline statistical 
Figure 3 Association between LVEF recovery at 2 years 
and mortality. survival probability for patients LVEF >50% at 
2 years is depicted in red, survival probability of patients with 
LVEF <50% at 4 months is depicted in black. For each year 
mark on the X- axis the number of subjects at risk in the two 
groups is reported above the axis, LVEF <50% on top, LVEF 
>50% on the bottom. Kaplan- Meier log- rank test p<0.01. 
LVEF, left ventricular ejection fraction.
Table 5 Relationship between LVEF recovery at 2 years 
and mortality
HR (CI) P value
LVEF recovery at 2 years 0.41 (0.21 to 0.80) 0.009
Age, per decade 1.36 (1.20 to 1.54) <0.0001
Female gender 0.57 (0.39 to 0.83) 0.003
Diabetes 1.24 (0.99 to 1.55) 0.066
Medical therapy vs CABG 1.44 (1.14 to 1.80) 0.002
BMI 1.00 (0.97 to 1.03) 0.947
OMT 0.95 (0.74 to 1.20) 0.652
Cox proportional hazard model of the relationship between LVEF 
recovery at 2 years and mortality during follow. For each variable, 
the HR for mortality during follow- up after adjusting for all other 
listed variables is indicated. 95% CI for the HR is reported 
in parentheses. Medical therapy vs CABG refers to patients 
randomised to medical therapy alone or to CABG plus medical 
therapy. OMT refers to patient on OMT at 4 months follow- up.
Statistical testing performed using Cox proportional hazard model.
BMI, body mass index; CABG, coronary artery bypass graft; OMT, 
optimal medical therapy.
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significance (table 2), but this is unlikely to explain 
our findings. We hypothesise that the increase in LVEF 
observed at short- term follow- up may result from changes 
in cardiovascular parameters, and therefore may not 
necessarily reflect the beneficial, progressive structural 
myocardial changes that have been classically associated 
with normalisation in LVEF and improved outcomes.2 22 
Further work will be needed to explore this hypothesis. 
Until data are gathered, clinicians caring for patients 
with HFrEF of ischaemic origin should interpret rapid 
normalizations in LVEF with caution.
Limitations
A strength of this study is that it is the first to examine EF 
normalisation in patients with ICM. It is also the first to 
investigate the prognostic significance of normalised EF 
using clinical trial data. However, our work has several 
limitations that should be acknowledged. First, the echo-
cardiographic measurements of LVEF collected in the 
STICH trial were not all obtained with the same method. 
It has been previously determined that the mean absolute 
differences between LVEF as determined by different 
echocardiographic methods in the STICH trial were 
minimal (mean absolute difference 2.7% for biplane 
and visual, 3.0% for single plane and visual and 2.9% for 
biplane and single plane),23 but we cannot exclude the 
possibility that these small differences biased our find-
ings. Second, normalisation of LVEF in patients with ICM 
is a rare event and therefore the number of patients with 
recovered LVEF that we analysed is small. These small 
numbers might reduce the reliability of our conclusions. 
Third, LVEF at 4 months was measured at 4 months from 
randomisation and not at 4 months from institution of 
therapy.24 Because some patients in the STICH trial expe-
rienced a delay between randomisation and initiation 
of therapy,11 the timing of this early assessment of LVEF 
normalisation might be inaccurate. Fourth, management 
of HFrEF has, to some extent, changed since the STICH 
trial and therefore our findings might not completely 
apply to contemporary patient cohorts. Fifth, while we 
know what classes of medications patients were on at 4 
months postdischarge, we do not know the exact doses 
prescribed. Lastly, as with any non- prespecified secondary 
analysis of subgroup of patients within trial populations, 
our study should be considered as hypothesis generating 
and our findings will need to be confirmed in other 
studies.
Conclusions
In patients with HFrEF and ICM, normalisation of LVEF 
is a rare event. In this patient population, normalisation 
of LVEF soon after initiation of therapy did not corre-
late with sustained normalisation of LVEF and might not 
constitute a positive prognostic sign. Instead, normalisa-
tion of LVEF at 2 years after initiation of therapy corre-
lated with a marked reduction in mortality risk during 
follow- up. Further studies will be needed to confirm 
these findings.
Twitter Walter B Schiffer @WalterBSchiffer, Andrew Perry @Perrycardium, David L 
Brown @DavidLBrownMD and Luigi Adamo @luigiadamomphd
Contributors All authors contributed to the design of the study. ED led the data 
analysis. All authors contributed to writing and reviewing the manuscript.
Funding Dr Adamo was supported by the NIH grant 1K08HL145108- 01A1.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access 
repository. Deidentified participant data from the STICH dataset was obtained 
from the NHLBI under a data use agreement. The Washington University Human 
Research Protection Office granted this study an exemption from Institutional 
Review Board oversight due to the deidentified nature of the data. This study 
complies with the Declaration of Helsinki.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Walter B Schiffer http:// orcid. org/ 0000- 0002- 2046- 1993
David L Brown http:// orcid. org/ 0000- 0002- 0930- 9747
Luigi Adamo http:// orcid. org/ 0000- 0003- 2704- 978X
REFERENCES
 1 Adamo L, Perry A, Novak E. Global longitudinal strain predicts 
sustained recovery of LV ejection fraction in heart failure patients on 
evidence based medical therapies. J Am Coll Cardiol 2017;69:727.
 2 Mann DL, Barger PM, Burkhoff D. Myocardial recovery and the 
failing heart: myth, magic, or molecular target? J Am Coll Cardiol 
2012;60:2465–72.
 3 Basuray A, French B, Ky B, et al. Heart failure with recovered 
ejection fraction: clinical description, biomarkers, and outcomes. 
Circulation 2014;129:2380–7.
 4 Cioffi G, Stefenelli C, Tarantini L, et al. Chronic left ventricular failure 
in the community: prevalence, prognosis, and predictors of the 
complete clinical recovery with return of cardiac size and function 
to normal in patients undergoing optimal therapy. J Card Fail 
2004;10:250–7.
 5 Lupón J, Díez- López C, de Antonio M, et al. Recovered heart failure 
with reduced ejection fraction and outcomes: a prospective study. 
Eur J Heart Fail 2017;19:1615–23.
 6 Merlo M, Pyxaras SA, Pinamonti B, et al. Prevalence and prognostic 
significance of left ventricular reverse remodeling in dilated 
cardiomyopathy receiving tailored medical treatment. J Am Coll 
Cardiol 2011;57:1468–76.
 7 Merlo M, Stolfo D, Anzini M, et al. Persistent recovery of normal 
left ventricular function and dimension in idiopathic dilated 
cardiomyopathy during long‐term follow‐up: does real healing exist? 
J Am Heart Assoc 2015;4:e001504.
 8 Givertz MM, Mann DL. Epidemiology and natural history of recovery 
of left ventricular function in recent onset dilated cardiomyopathies. 
Curr Heart Fail Rep;10:321–30.
 9 Basuray A, Fang JC. Management of patients with recovered systolic 
function. Prog Cardiovasc Dis 2016;58:434–43.
 10 Klem I, Shah DJ, White RD, et al. Prognostic value of routine cardiac 
magnetic resonance assessment of left ventricular ejection fraction 
and myocardial damage: an international, multicenter study. Circ 
Cardiovasc Imaging 2011;4:610–9.
 11 Velazquez EJ, Lee KL, Deja MA, et al. Coronary- artery bypass 
surgery in patients with left ventricular dysfunction. N Engl J Med 
2011;364:1607–16.
 12 Velazquez EJ, Lee KL, Jones RH, et al. Coronary- artery bypass 
surgery in patients with ischemic cardiomyopathy. N Engl J Med 
2016;374:1511–20.
 13 Velazquez EJ, Lee KL, Deja MA. Coronary- artery bypass surgery in 
patients with left ventricular dysfunction. New England Journal of 
Medicine 2011;364:1607–16.
 14 Pellikka PA, She L, Holly TA, et al. Variability in ejection fraction 
measured by echocardiography, gated single- photon emission 
computed tomography, and cardiac magnetic resonance in patients 
 on M












7Schiffer WB, et al. Open Heart 2021;8:e001528. doi:10.1136/openhrt-2020-001528
Heart failure and cardiomyopathies
with coronary artery disease and left ventricular dysfunction. JAMA 
Netw Open 2018;1:e181456–e56.
 15 Perry AS, Mann DL. Brown DLImprovement of ejection fraction and 
mortality in ischaemic heart failureHeart (Published Online First: 25 
August 2020).
 16 Lupón J, Gavidia- Bovadilla G, Ferrer E, et al. Dynamic trajectories 
of left ventricular ejection fraction in heart failure. J Am Coll Cardiol 
2018;72:591–601.
 17 Monge García MI, Jian Z, Settels JJ, et al. Determinants of left 
ventricular ejection fraction and a novel method to improve 
its assessment of myocardial contractility. Ann Intensive Care 
2019;9:48.
 18 Maurer MS, Sackner- Bernstein JD, El- Khoury Rumbarger L, et al. 
Mechanisms underlying improvements in ejection fraction with 
carvedilol in heart failure. Circ Heart Fail 2009;2:189–96.
 19 Florea VG, Rector TS, Anand IS, et al. Heart failure with improved 
ejection fraction: clinical characteristics, correlates of recovery, and 
survival: results from the valsartan heart failure trial. Circ Heart Fail 
2016;9:e003123.
 20 Chang K- W, Beri N, Nguyen NH, et al. Heart failure with recovered 
ejection fraction in African Americans: results from the African- 
American heart failure trial. J Card Fail 2018;24:303–9.
 21 de Groote P, Fertin M, Duva Pentiah A, et al. Long- Term functional 
and clinical follow- up of patients with heart failure with recovered left 
ventricular ejection fraction after β-blocker therapy. Circ Heart Fail 
2014;7:434–9.
 22 Adamo LM, Douglas L. Alterations in Ventricular Function: Role 
of Left Ventricular Remodelling and Reverse Remodelling in Heart 
Failure. In: DMaG F, ed. Heart Failure -A companion to Braunwald’s 
Heart Disease. 3rd edn. Philadelphia: Elsevier, 2016: 178–94.
 23 Mitchell C, Rahko PS, Blauwet LA. Guidelines for performing a 
comprehensive transthoracic echocardiographic examination 
in adults: recommendations from the American Society of 
echocardiography. J Am Soc Echocardiogr;32:1–64.
 24 Velazquez EJ, Lee KL, O'Connor CM, et al. The rationale and design 
of the surgical treatment for ischemic heart failure (STICH) trial. J 
Thorac Cardiovasc Surg 2007;134:1540–7.
 on M













Supplementary Table 1. Comparison of Patients with and without LVEF Assessment at 30 
Days 
 
 30-Day LVEF 
Available (N=885) 
No 30-Day LVEF 
(N=47) 
p-value 
Age (SD) 60.58 (9.26) 59.46 (9.80) 0.42 
BMI (SD) 27.44 (4.70) 26.91 (5.14) 0.449 
Medical Therapy vs 
CABG (%) 
455 (51.4) 21 (44.7) 0.453 
Male Gender (%) 768 (86.8) 42 (89.4) 0.772 
Diabetes (%) 368 (41.6) 17 (36.2) 0.56 
CRI (%) 60 (6.8) 4 (8.5) 0.557 
OMT (%) 579 (65.4) 33 (70.2) 0.606 
ICD (%) 22 (2.5) 2 (4.3) 0.344 
 
BMI= body mass index; Medical therapy vs CABG= patients randomized to medical therapy 
alone or to coronary artery bypass graft plus medical therapy; CRI= cardiac resynchronization 
therapy; OMT= patient on optimal medical therapy at 30 days follow-up; ICD= permanent 
implanted cardiac defibrillator. Data presented as mean (standard deviation) for continuous 
variables and number (percentage) for categorical variables. Statistical testing performed using t-
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Supplementary Table 2. Comparison of Patients with and without LVEF Assessment at 2 
Years 
 
 2-Year LVEF 
Available (N=634) 
No LVEF at 2 
Years (N=201) 
p 
Age (SD) 60.26 (9.16) 59.94 (9.14) 0.665 
BMI (SD) 27.48 (4.63) 27.30 (5.00) 0.639 
Medical Therapy vs 
CABG (%) 
321 (50.6) 96 (47.8) 0.53 
Male Gender (%) 542 (85.5) 184 (91.5) 0.036 
Diabetes (%) 262 (41.3) 72 (35.8) 0.192 
CRI (%) 40 (6.3) 11 (5.5) 0.738 
OMT (%) 430 (67.8) 127 (63.2) 0.258 
ICD (%) 13 (2.1) 5 (2.5) 0.78 
 
BMI= body mass index; Medical therapy vs CABG= patients randomized to medical therapy 
alone or to coronary artery bypass graft plus medical therapy; CRI= cardiac resynchronization 
therapy; OMT= patient on optimal medical therapy at 30 days follow-up; ICD= permanent 
implanted cardiac defibrillator. Data presented as mean (standard deviation) for continuous 
variables and number (percentage) for categorical variables. Statistical testing performed using t-
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